Scholarlink

<p>Cancer-associated microRNAs are promising biomarkers for early cancer diagnosis. However, current microRNA detections – which are based on polymerase chain reaction, microarray analysis, Raman scattering, or various electrochemical assays – rely on multi-step analysis including amplification of microRNA and/or read-out signals, often causing inaccuracy despite using elaborate instruments, which remains a major challenge. Here, we describe an RNaseH1-dependent, amplification-free detection of microRNAs, which is based on Förster resonance energy transfer (FRET) between donor (single-stranded DNA probe (ssDNA)-spiked, green fluorescent nanocage) and acceptor (RNaseH1-linked, orange fluorescent protein) and enables reliable cancer diagnosis with high accuracy for human lung and gastric cancer patients and healthy donors by directly quantifying serum microRNA targets. Notably, unlike traditional ensemble FRET, this FRET platform senses molecular interactions between ssDNA and miRNAs and conformational changes of their hybrid helices and thus differentiates even a single-base mismatch, which holds significant promise for reliable, clinical cancer diagnosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An RNase domain-dependent microRNA detection with DNA-spiked nanocage for accurate cancer diagnosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Hye Hyun Kim,
  • Yong Hwan Seol,
  • Dae Kwon Park,
  • Young Eun Jang,
  • Jeewon Lee

摘要

Cancer-associated microRNAs are promising biomarkers for early cancer diagnosis. However, current microRNA detections – which are based on polymerase chain reaction, microarray analysis, Raman scattering, or various electrochemical assays – rely on multi-step analysis including amplification of microRNA and/or read-out signals, often causing inaccuracy despite using elaborate instruments, which remains a major challenge. Here, we describe an RNaseH1-dependent, amplification-free detection of microRNAs, which is based on Förster resonance energy transfer (FRET) between donor (single-stranded DNA probe (ssDNA)-spiked, green fluorescent nanocage) and acceptor (RNaseH1-linked, orange fluorescent protein) and enables reliable cancer diagnosis with high accuracy for human lung and gastric cancer patients and healthy donors by directly quantifying serum microRNA targets. Notably, unlike traditional ensemble FRET, this FRET platform senses molecular interactions between ssDNA and miRNAs and conformational changes of their hybrid helices and thus differentiates even a single-base mismatch, which holds significant promise for reliable, clinical cancer diagnosis.